Elite Ships US Generic Adderall Amid Ongoing Shortages

Shortage Of Vital ADHD Drug Ongoing Since 2019

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

As the nationwide shortage of Adderall continues in the US, Elite Pharmaceuticals has announced the first shipment of its generic version to partner Prasco.

Adderall XR in an orange pill bottle
The Adderall shortage has been blamed on numerous factors, including increased demand and restrictive quotas • Source: Shutterstock

Specialty pharmaceutical company Elite Pharmaceuticals, Inc. has announced the first shipment of its generic Adderall (mixed amphetamine salts) to distribution and marketing partner Prasco Laboratories, LLC. Prasco is a non-exclusive US distributor of the drug, and will market it under the Burel Pharmaceutical label, while Elite will be responsible for manufacturing.

Key takeaways:

  • Elite has announced the first shipment of its generic Adderall to its distribution and marketing partner Prasco, which will market the drug in the US under the Burel Pharmaceutical label

The generic is available in strengths of 5mg, 10mg, 15mg, 20mg, 25mg and 30mg.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Warns Over Delays From Toyama Plant

Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.